Literature DB >> 25800413

Vitiligo in adults and children: surgical interventions.

Rubeta Matin1.   

Abstract

INTRODUCTION: Vitiligo is an acquired skin disorder characterised by white (depigmented) patches in the skin, due to the loss of functioning melanocytes. The extent and distribution of vitiligo often changes during the course of a person's lifetime and its progression is unpredictable. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of surgical interventions for vitiligo in adults and in children? We searched: Medline, Embase, The Cochrane Library, and other important databases up to April 2014 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found four studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: blister grafts, cultured cellular transplantation, non-cultured cellular transplantation, punch/mini grafts, and split thickness skin grafts.

Entities:  

Mesh:

Year:  2015        PMID: 25800413      PMCID: PMC4371616     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  43 in total

1.  Novel vitiligo susceptibility loci on chromosomes 7 (AIS2) and 8 (AIS3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis.

Authors:  Richard A Spritz; Katherine Gowan; Dorothy C Bennett; Pamela R Fain
Journal:  Am J Hum Genet       Date:  2004-01       Impact factor: 11.025

Review 2.  Vitiligo puzzle: the pieces fall in place.

Authors:  Wiete Westerhof; Marco d'Ischia
Journal:  Pigment Cell Res       Date:  2007-10

3.  The provocation of cutaneous disease; Köbner's isomorphic phenomenon.

Authors:  F R BETTLEY
Journal:  Arch Middx Hosp       Date:  1951-10

Review 4.  Surgical interventions for vitiligo: an evidence-based review.

Authors:  S V Mulekar; P Isedeh
Journal:  Br J Dermatol       Date:  2013-10       Impact factor: 9.302

5.  Guidelines of care for vitiligo. American Academy of Dermatology.

Authors:  L A Drake; S M Dinehart; E R Farmer; R W Goltz; G F Graham; M K Hordinsky; C W Lewis; D M Pariser; J W Skouge; M L Turner; S B Webster; D C Whitaker; B J Lowery; J J Nordlund; P E Grimes; R M Halder; H R Minus
Journal:  J Am Acad Dermatol       Date:  1996-10       Impact factor: 11.527

6.  The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions.

Authors:  M S Al'Abadie; G G Kent; D J Gawkrodger
Journal:  Br J Dermatol       Date:  1994-02       Impact factor: 9.302

7.  Autologous epidermal cultures and narrow-band ultraviolet B in the surgical treatment of vitiligo.

Authors:  Elisa Pianigiani; Massimiliano Risulo; Andrea Andreassi; Paolo Taddeucci; Francesca Ierardi; Lucio Andreassi
Journal:  Dermatol Surg       Date:  2005-02       Impact factor: 3.398

8.  Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo.

Authors:  Nanny van Geel; Katia Ongenae; Martine De Mil; Yves Vander Haeghen; Chris Vervaet; Jean Marie Naeyaert
Journal:  Arch Dermatol       Date:  2004-10

9.  Psychological reaction to chronic skin disorders: a study of patients with vitiligo.

Authors:  J Porter; A H Beuf; J J Nordlund; A B Lerner
Journal:  Gen Hosp Psychiatry       Date:  1979-04       Impact factor: 3.238

10.  A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.

Authors:  Veronica Lepe; Benjamin Moncada; Juan Pablo Castanedo-Cazares; Maria Bertha Torres-Alvarez; Carlos A Ortiz; Antonio B Torres-Rubalcava
Journal:  Arch Dermatol       Date:  2003-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.